Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 608-612, 2017.
Article
in Zh
| WPRIM
| ID: wpr-271950
Responsible library:
WPRO
ABSTRACT
Drug resistance of multiple myeloma(MM) has become more and more common, and greatly decreased the survival rate of these patients. The occurence of drug-resistance involves in many factors such as bone marrow microenveronment, tumor cell self-metabolism, cytokines, specific targets and so on. In this review, the potential mechanisms of resistance to glucocorticoid/proteasome inhibitor/immunomodulatory druges are briefly expounded in the aspect of tumor cell self-metabolism, including the changes of heat slock protein expression, mRNA expression, related cytokine levels and down-regulation of thalidomid-effecting site CRBN expression. In this review, the researches on the effect of histone deacetylase inhibitors(HDACi) combined with glucocorticoid, proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies on multiple myeloma, specially, drug-resistant multiple myeloma are also summarized.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2017
Type:
Article